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Acute respiratory infections are a major cause of morbidity in children both in developed and developing countries.
A wide range of respiratory viruses, including respiratory syncytial virus (RSV), influenza A and B viruses,
parainfluenza viruses (PIVs), adenovirus, rhinovirus (HRV), have repeatedly been detected in acute lower respiratory
tract infections (LRTI) in children in the past decades. However, in the last ten years thanks to progress in molecular
technologies, newly discovered viruses have been identified including human Metapneumovirus (hMPV),
coronaviruses NL63 (HcoV-NL63) and HKU1 (HcoV-HKU1), human Bocavirus (HBoV), new enterovirus (HEV),
parechovirus (HpeV) and rhinovirus (HRV) strains, polyomaviruses WU (WUPyV) and KI (KIPyV) and the pandemic
H1N1v influenza A virus. These discoveries have heavily modified previous knowledge on respiratory infections
mainly highlighting that pediatric population is exposed to a variety of viruses with similar seasonal patterns. In this
context establishing a causal link between a newly identified virus and the disease as well as an association
between mixed infections and an increase in disease severity can be challenging. This review will present an
overview of newly recognized as well as the main emerging respiratory viruses and seek to focus on the their
contribution to infection and co-infection in LRTIs in childhood.Introduction
In the last decade thanks to progress in molecular
technologies, newly discovered viruses have been identi-
fied. In 2001 human Metapneumovirus (hMPV) was
identified, followed by discoveries or emergence of other
respiratory viruses or virus strains: coronaviruses NL63
(HcoV-NL63) and HKU1 (HcoV-HKU1), human Boca-
virus (HBoV), new enterovirus (HEV), parechovirus
(HpeV) and rhinovirus (HRV) strains, polyomaviruses
WU (WUPyV) and KI (KIPyV) and the pandemic
H1N1v influenza A virus [1-8].
These discoveries have heavily modified previous
knowledge on respiratory infections and have now high-
lighted that although until recently most viral lower
respiratory infections in infants and young children were
attributed to respiratory syncytial virus (RSV), PIVs,
adenovirus, HRV and influenza viruses, pediatric* Correspondence: canducci.filippo@hsr.it
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reproduction in any medium, provided the orpopulation is indeed exposed to a variety of other viruses
with a similar seasonal pattern [9-11]. In this context,
establishing a causal link between a newly identified
virus and the disease as well as an association between
mixed infections and an increase in disease severity can
be challenging. This review will present a brief overview
of newly recognized as well as the main emerging re-
spiratory viruses and seek to focus on the their contribu-
tion to infection and co-infection in LRTIs in childhood.Metapneumovirus
Metapneumovirus was first recognized in 2001 in the
Netherlands from nasopharyngeal aspirates collected dur-
ing a 20-year period in 28 hospitalized children and infants
with acute respiratory tract infection (RTI) having signs and
symptoms similar to that of RSV infection [4]. The virus
genomic sequence was identified by using a randomly
primed PCR protocol and revealed to be closely related to
the avian pneumovirus, a member of the Metapneumovirus
genus, in the Paramixoviridae family, Initial studies follow-
ing the first hMPV identification indicate that it causesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Debiaggi et al. Virology Journal 2012, 9:247 Page 2 of 18
http://www.virologyj.com/content/9/1/247upper and lower RTIs in patients of all ages, but mostly in
children aged below 5 years [12-17]. A large epidemio-
logical retrospective study examined nasal washes collected
over a 20-year period during acute respiratory illnesses in
an outpatient cohort of children [18]. Over the entire study
period, hMPV was detected in 1%-5% of pediatric upper
RTIs (UTRIs), with variation from year to year. Several
reports indicate that hMPV is a commonly identified cause
of pediatric lower RTIs, and is second only to RSV as cause
of bronchiolitis in early childhood [16,19-25]. While bron-
chiolitis, is the most common presentation of hMPV ill-
ness, other reported syndromes have included asthma
exacerbation, otitis media, flulike illness, and community-
acquired pneumonia [12,15,26-29]. Several studies have
found hMPV –RSV co-infection rates of approximately 5-
14% [30-34]. Nevertheless, in a study conducted in the
Netherlands in children admitted to hospital for lower RTIs
(LRTIs), no virus co-infection between RSV and hMPV was
detected [35]. Different controversial reports suggest an as-
sociation between RSV-hMPV coinfection and an increase
in the disease severity or the absence of an association be-
tween dual infection and disease severity. Greensill and col-
leagues [36] reported a 70% rate of co-infection with hMPV
in a cohort of infants with critical RSV bronchiolitis who
required intensive care in the United Kingdom, suggesting
that dual infection with RSV and hMPV may predispose for
a more severe disease. In another study from the United
Kingdom, hMPV and RSV co-infection was associated with
increased disease severity and higher risk of admission to
the pediatric intensive care unit [37]. Similar findings are
supported by other studies suggesting that in young chil-
dren, coinfections with RSV and hMPV are more severe
than infections with either RSV or hMPV alone, requiring a
longer hospitalization and supplemental oxygenation
[38,39]. However, such synergistic association has not been
found in other population-based and case–control studies
of hospitalized children [16,33-35,40-42]. In particular, two
studies evaluated the epidemiology of hMPV coinfection in
children with LRTI caused by RSV and demonstrated no
hMPV and RSV co-infection in mechanically ventilated
children suggesting that co-infection with hMPV is not
associated with a more severe course of RSV-LRTI [35,42].
In addition, in a prospective 2-year study in hospitalized
infants with acute respiratory diseases, the role of RSV as a
major respiratory pathogen was not influenced by the co-
circulation of other emerging viral agents with similar sea-
sonal distribution. In particular, RSV-hMPVs co-infections
were significantly observed in less severe respiratory disease
when compared to unique RSV infections [34]. The pos-
sible synergistic interaction between hMPV and the severe
acute respiratory syndrome (SARS) coronavirus was also
suggested during the 2003 SARS outbreak in Hong Kong
and Canada [43,44]. In one case report, in an infant with
SARS CoV infection, fatal encephalitis was correlated withhMPV infection as hMPV RNA was detected post-
mortem in brain and lung tissue [26]. Nevertheless, in
experimental studies performed in macaques, a synergy
between hMPV and SARS was not confirmed [45]. In
addition, infections of hMPV with respiratory viruses
different from RSV, have also been occasionally reported
but no sufficient data are available to discuss epidemi-
ology or association with clinical disease presentation
[34,46,47] (Table 1).
Coronaviruses
Following the discovery of SARS-CoV, other human coro-
naviruses, HCoV-NL63 and HCoV-HKU1, were identified
and recognized to be common causes of community-
acquired respiratory infections.
HCoV-NL63, a member of the group I coronaviruses,
was first detected in 2004 in the Netherlands from a
child with bronchiolitis by using a new method for
virus discovery based on the cDNA-amplified restric-
tion fragment−length polymorphism technique (cDNA-
AFLP) [3].
HCoV-HKU1, a group II coronavirus, was first detected
in Hong Kong in 2005 from an adult patient with chronic
pulmonary disease [1]. All attempts to grow a virus from
his respiratory secretions failed until recently [48], but cor-
onavirus RNA was initially detected by RT-PCR using pol
gene consensus primers.
Like other coronaviruses, NL63 and HKU1 can also be
detected in individuals of all ages, including elderly
patients with fatal outcome [49] and those with under-
lying diseases of the respiratory tract [1]. However most
frequently, the newly discovered coronaviruses are
reported in 7 to 12-month old children with both upper
and lower RTIs [34,49-53]. In studies conducted in chil-
dren hospitalized with RTIs in China, from 2.6% to 3.8%
of patients were positive for HCoV-NL63 and, in
addition to causing upper respiratory disease, HCoV-
NL63 was found in croup, asthma exacerbation, febrile
seizures, wheezing and high fever cases [54,55]. The oc-
currence of co-infection with NL63 and other respira-
tory viruses, including other human coronaviruses, RSV,
PIV, influenza A and B viruses and hMPV has been
reported [34,55-58]. In a large study from Germany
evaluating children under 3 years of age with LRTIs,
most co-infections were with RSV-A, probably because
of the high percentage of RSV-A infections and an over-
lap in seasonality. In addition, double infection of NL63
with RSV-B, and with PIV3 occurred in a minority of
cases. HCoV-NL63 co-infection with RSV-A occurred
predominantly in the hospitalised patients in contrast to
HCoV-NL63 co-infections with PIV3 that were exclu-
sively present in the outpatient group [59].
Following the first identification, HKU1 was found in
respiratory samples from elderly patients and children
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common symptoms are rhinorrhea, fever, and abdominal
breath sounds [33], but pneumonia, bronchopneumonia,
bronchiolitis, and acute asthma exacerbations were also
described in children in China [61,62].
In a study aimed to evaluate the overall prevalence of
10 respiratory viruses in children with acute LRTIs in
China from 2006 to 2009, 73.47% of the HCoV-HKU1
and HCoV-NL63-positive samples tested positive for at
least one other virus, most commonly HRV and RSV
[54]. Similar data describing a high rate of coinfection of
coronaviruses with RSV has also been previously
reported [63]. In a report from the UK both dual and
single infections associated with respiratory outcomes
were observed for HKU1 as well as for NL63 and OC43
coronaviruses [51]. In this study a high number of coin-
fections was observed for HKU1, NL63 as well as for
OC43, mostly with RSV. Similar rates of lower and
upper infections were observed in single HKU1 or OC43
infection compared with coinfection, whereas both URTI
and LRTI were observed more frequently in single com-
pared to mixed infection with NL63. No differences in
clinical outcome were observed between single and dual
infections with RSV and Coronaviruses NL63, HKU1 or
OC43 indicating that RSV may presumably facilitate cor-
onavirus infection without increasing disease severity.
However, in the same study considering viral load data,
a role of these coronaviruses in coinfections in respira-
tory disease was suggested. In fact no differences were
observed when coronavirus load was evaluated in single
infection and in RSV coinfection, indicating both that in-
fection with another respiratory virus does not affect the
ability of NL63, HKU1 or OC43 to establish infection
and replicate, and that detection of coronaviruses in
mixed infection should not be considered a secondary
infection without contribution to disease pathogenesis
[51]. This quantitative evaluation is in contrast with pre-
vious results obtained by van der Hoek and colleagues
describing a significantly lower HCoV-NL63 viral load in
patients coinfected with RSV or PIV3 than in patients
infected with HCoV-NL63 alone [59]. However, the pro-
longed persistence of HCoV-NL63 at low levels, the dif-
ferent time of sampling relative to the time of disease
onset, or the use of different diagnostic technologies
could have affected these evaluations (Table 1).
Bocavirus
Human Bocavirus (HBoV) was discovered in 2005, in
Sweden by Allander and colleagues by using a large-
scale molecular viral screening technique including
DNase sequence-independent single-primer amplifica-
tion [6]. Since initial observations, several studies have
reported the prevalence of human Bocavirus infection all
over the world ranging from 2 to 21.5%, mainly inchildren younger than 3 years of age where it has been
associated with upper and with lower RTIs [64-69]. In a
study from Norway, HBoV was detected in 12% of chil-
dren with RTI and it was the fourth most common virus
after RSV, HRV and hMPV [70]. Recently, in children
with radiographically confirmed community acquired
pneumonia in which 17 respiratory viruses were tested
during the acute phase of the disease, HBoV was the
most frequently detected virus after RSV and HRV [71].
Since the discovery of the first HBoV (HBoV1), three
other related bocaviruses (HBoV2, 3 and 4) have been
identified in stool samples and associated with gastro-
intestinal diseases [72,73]. Serological studies on HBoV1
are in line with molecular data.
Serological studies have shown that the mere presence
of HBoV DNA in the respiratory tract is not proof of an
acute primary infection [65,74-76]. These data are also
supported by studies on consecutive respiratory samples
showing that HBoV DNA can persist for several months
in the respiratory tract [77-79]. Prolonged viral shedding
could explain both data reported in some papers in
which HBoV DNA was found more often in asymptom-
atic than symptomatic cases [79,80] and the high per-
centage of co-infections. In fact, HBoV infections tend
to be associated with high rates of coinfections with
other viral pathogens such as HRV, adenoviruses, RSV,
as well as with bacteria such as Streptococcus spp and
Mycoplasma pneumoniae [46,54,68-70,77,81-83]. Char-
acteristics of persistence and high frequency of coinfec-
tions have led to a debate over its role as a true
pathogen [84]. Our current knowledge of HBoV infec-
tion suggests that the virus is sometimes a passenger
and sometimes a pathogen in acute respiratory tract dis-
ease and that diagnosis should not be solely based on
qualitative PCR in respiratory samples. Indeed, in many
studies a positive correlation was seen between respira-
tory illness and high copy numbers of HBoV1 DNA or
the presence of HBoV1 monoinfection [68,75,85-87]. A
study performed by Allander and colleagues suggests
that acute HBoV infections are associated with the pres-
ence of viral DNA in the blood of patients. In fact,
HBoV DNA was reported more frequently in patient
blood during the acute symptoms than after recovery
[68]. In addition, high load and viremic HBoV infection
were associated with respiratory tract symptoms, while
detection of a low viral load in the nasopharinx alone
resulted to have no clinical relevance [68]. Other studies
confirmed that HBoV is the most probable cause of re-
spiratory tract disease if the patient has a single infection
and high viral load in NPA and viremia [65,70]. How-
ever, despite these diagnostic challenges it is becoming
increasingly evident that HBoV1 is an important respira-
tory pathogen [88]. Severe and life-threatening disease
has been recently well documented in a 8-month-old
Table 1 Recent epidemiological papers on respiratory infections and co-infections
PAPER VIRUSES ANALYSED (detection methods)





Xepapadaki, 2004 X(a) X(a) X(a) X(a) X(a) X(a)
Konig, 2004 X(a)
Semple, 2005 X(a)
van Woensel, 2006 X(b)
Foulongne, 2006 (d) (d) (d) X(a) (d)
Lazar, 2004 X(a)
Canducci, 2008 X(a)
Chiu, 2005 (d) (d) (d) X(a) (d)
van der Hoek,2006 X(a) X(a) X(a)
Dare, 2007
Kuypers, 2007 X(a) X(a) X(a) X(a)
Minosse, 2008 X(a) X(a)
Wu, 2008 X X
Gaunt, 2010 X(b) X(b) X(b) X(b)
Choi, 2006 X(a) and (d) X(a) and (d) X(a) X(a) and (d) X(a) X(a) and (d)
Allander, 2007 X(b), (c), (d), (e) X(b), (c), (d), (e) (c), (e), X(a) (c), (e), X(a) X(b), (c), (d), (e) (c), X(a) X(b), (d), (e)
Christensen, 2008 X(b) X(b) X(b) X(b) X(b) X(b) X(b)
Dina, 2009 X(a) X(a) X(a) X(a) X(a) (d), (c), X(b), x(a)
Wang, 2010 X(a) X(a) X(a) X(a) X(a) X(a)
Don, 2010 (e) (e) (e) (e) (e)
Soderlund-Venermo, 2009 X(a) X(a) X(a) X(a) X(a) X(a) X(a)
Martin, 2010 X(a) X(a) X(a) X(a) X(a) X(a)
Jin, 2012 X(a) X(a) X(a) X(a) X(a) X(a)
Esposito, 2012 X(a) X(a) X(b) X(b) X(a) X(a) X(a)
Le, 2007 X(a) X(a) X(a) X(a) X(a) X(a)
Han, 2007 X(a) X(a) X(a) X(a) X(a) X(a)
Bialasiewicz, 2008 X(a) X(a) X(a) X(a) X(a) X(a)
Neske, 2008 (d) (d) (d) (d)
Babakir-Mina, 2010
Debiaggi, 2010 X(a) X(a) X(a) X(a) X(a) X(a)
Zhuang, 2011 X(b) X(b) X(b) X(b) X(b) X(b)
Rao, 2011 X(a) X(a) X(a) X(a) X(a) X(a)
Lau, 2007 (d) (d) X(a) (d) X(a) (d)
Harvala, 2008 X(a) X(a) X(a) X(a) X(a) X(a)
Jin, 2009 X(a) X(a) X(a) X(a) X(a) X(a)
Miller, 2009 X(a)
Yozwiak, 2010 X(a)
Debiaggi, 2012 X(a) X(a) X(a) X(a) X(a) X(a) X(a)
Piralla, 2012 X(a) X(a) X(a) X(a) X(b) X(a) X(a) X(a)
Renois, 2010 X(a) X(a) and X(b) X(a) X(a) X(a) X(a) X(a) X(a)
Casalegno, 2010 X(b) X(b)
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Schnepf, 2011 X(b) X(a) X(a) X(a) X(a) X(a) X(a)
VIRUSES ANALYSED (detection methods) POPULATION CONCLUSIONS










X(a) pediatric (30, ventilated
and with bronchiolitis)
70% rates of co-infection




for a more severe disease.
(d) children <2 years (63)
with RTD
17,5% hMPV positive, 23%
RSV positive, 4.7% hMPV-RSV
coinfections. Similar
symptoms between
hMPV+ and RSV+ children.
children <5 years (688)
negative for RSV, PIV,
Flu A and B, ADV
8% hMPV positive samples
X(a) X(a) X(a) X(a) X(a) pediatric (56) with
acute bronchiolitis
16% bronchiolitis is hMPV




coinfections with RSV and
hMPV are more severe
than infections with
either RSV or hMPV alone
in young children
X(a) <2-year-old infants with
bronchiolitis(196)
hMPV and RSV co-infection
is associated with increased
disease severity
X(b) pediatric (30, mean
age 10 weeks, ventilated
and with bronchiolitis)
No virus co-infection
between RSV and hMPV
in a cohort of infants
with bronchiolitis
(d) 589 children hospitalized
with respiratory disease
<5 years
8.5% rates of hMPV infections,
the second leading cause
of RTD after RSV, 30% of the
cases are hMPV-RSV
coinfections. The duration of
hospitalization and
requirement for supplemental
oxygen were increased in case
of hMPV-RSV coinfections
X(a) 46 children with mild to
severe RSV disease
(PIV, fluA and B,
ADVnegative)
hMPV did not contribute
to the severity of RSV disease
X(a) X(a) X(a) X(a) X(a) X(a) 322 infant patients with
acute respiratory disease
RSV-hMPVs co-infections were








HCoV-NL63 can present as
croup, asthma exacerbation,
febrile seizures, and high fever.
X(a) X(b) children<3 years with
LRTIs (940)
HCoV-NL63 RNA was detected
in 5.2% of cases;43% of the
HCoV-NL63-positive patients
with high viral load and
absence of co-infection
suffered from croup. Most
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Table 1 Recent epidemiological papers on respiratory infections and co-infections (Continued)
co-infections were with
RSV-A HCoV-NL63 co-infection
with RSV-A occurred mainly
in hospitalised patients in
contrast to HCoV-NL63
co-infections with PIV3 that
were exclusively present in
the outpatient group. Lower
HCoV-NL63 viral load in
patients coinfected with
RSV or PIV3 than in patients
infected with HCoV-NL63 alone
X(b) X(b) X(b) X(b) 1156 patients with
pneumonia, 513 outpatients,
281 controls
1.8% of patients with
pneumonia, 2.3% of
outpatients and 2.1% of
controls had HCoV infections.
In control patients, infection
with any HCoV type or with
all types combined was not
associated with pneumonia
X(a) X(b) X(b) X(b) X(b) 1043 pediatric (0–19 years old)
respiratory specimens
CoVs were detected in 6.3%
of specimens. 45.5%
CoV-positive specimens
also had another respiratory
virus detected, most commonly
RSV (67%). CoV subtypes NL63
and HKU1 accounted for the
majority of CoVs detected.
X(a) hospitalized adult patients
(433, mean age 56 years)
2% Hcov NL63 positive, 33%
coinfected NL63-HRV, 10%
coinfected NL63-ADV
X X(b) 539 children < 15 years
with respiratory disease
1.3% HCoV NL63 positive,
43% of HCoV infection are
coinfections (RSV, ADV, hMPV)
X(b) X(b) X(b) X(b) X(b) 11661 respiratory samples high rate of coinfections
observed for HKU1, NL63
and OC43, mostly with RSV.
No d(d)ferences of HCoV
viral load were observed
between single infection
and RSV coinfection. Detection
of CoVs should not be
interpreted as representing an
incidental infection without
contribute to disease.
X(a) and (d) X(a) X(a) X(a) X(a) 515 children< 5 years old
with LRTIs
The prevalence of HboV was
the second (11%), the first
was RSV (23%). Among HBoV
infections, a high rate (38%)
was coinfection.
(c), (d), (e), X(a) X(a) X(a) X(b), (e) X(b), (e) X(b), (e) 259 children (median age,
1.6 years) who had been
hospitalized for acute
expiratory wheezing
Acute HBoV infections appears
associated with presence of
viral DNA in the blood as the
HBoV DNA was reported more
prevalent in the patients blood
during the acute symptoms
than after recovery. High load
and viremic HBoV infection
were associated with
respiratory tract symptoms,
while detection of a low viral
load in the nasopharinx alone
has uncertain relevance
X(b) X(b) X(b) X(b) X(b) HBoV was detected in 12% of
samples. It was the fourth most
common virus in the material
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after RSV (25%), HRV (17%) and
hMPV(14%). Multiple viral
infections were common
and were present in 78%
of the samples, more
commonly RSV
X(b), X(a) 842 patients hospitalized
with respiratory symptoms
(mean age 22 years)
The prevalence of HBoV
infection was 3.8%. HBoV.
Viral load appears to be
linked to the severity of
the disease.
X(a) X(a) X(a) X(a) X(a) X(a),X(b), (e) 817 children with
respiratory tract
infection
HBoV was ident(d)ied in
12% of samples. Co-infection
rate with other respiratory
viruses was 51%. HBoV was
found frequently in children
with respiratory tract
symptoms associated with
other viruses, and persisted
in the respiratory tract, in
serum and urine. The
presence of IgM was
significantly more prevalent
in viremic patients and those
diagnosed with high load of
HBoV DNAin nasal/throat
swabs
(e) (e) 124 children with
presumptive pneumonia
<15 years
Mixed infections were found
in 25% of cases. Serological
evidence of acute HBoV
infection was found in 12%
of children with pneumonia
and in more than half of
cases with single HBoV
infection.This suggests that
HBoV may be a fairly
common cause of
pneumonia in children
X(a) X(a) X(a) X(a) X(a) X(a), (e), X (b) 259 weezing children





children with no signs of
other respiratory virus
infections demonstrate
that HBoV is a cause of
acute wheezing in young
children. Accurate HBoV
diagnosis requires serologic
analysis or PCR of serum,
PCR of NPAs alone is
insufficient. HBoV is the
most probable cause of
respiratory tract disease
(d) the patients has single
infection, a high viral load
in NPA nasopharyngeal
aspirates and viremia
X(a) X(a) X(a) X(a) X(a) X(b) 119 children
attending daycare
28% tested positive for
HBoV. HBoV was detected
significantly more often
than any of the 14
respiratory viruses but HRVs.
HboV DNA can persist for
several months in the
respiratory tract
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by HRV (20%), HBoV
(11.5%), PIV1-3 (8%),
AdV (7.5%), FluA (7%),
HMPV (6.%), NL63 (4%),
HKU1 (2.%) and FluB
(0.98%). Of the HCoV-HKU1
and HCoV-NL63-positive
samples, 74% were
co-infected with at least
another virus, most
commonly HRV and RSV.
X(a) X(a) X(a) X(a) X(a) X(a) 592 children with
radiographically
confirmed pneumonia
HBoV was the most
frequently detected
virus(10%) after RSV
(31%) and HRV (24%)
X(a) X(a) X(a) X(a) X(b) 2,263 samples from
children <4 years of
age and 374 from









the sole virus detected
in 20 specimens from
patients with respiratory
illness, which suggests





that it may persistently
infect humans





in 7% children with
LARD, 4.2% of
asymptomatic children
and as coinfection with
other respiratory viruses
in 67.6%. Although WUPyV
was frequently detected,
its clinical role has not
been distinguished from
that of coinfecting viruses
X(a) X(a) X(a) X(a) X(a) X(b) X(b) X(b) 2866 respiratory sample
from people with acute
respiratory diseases
(mean age 9.2 years)
KIV and WUV were found
at a prevalence of 2.6%
and 4.5%, respectively.
Level of co-infection of KIV
or WUV with other viruses
was 74.7% and 79.7%,
respectively. It is not
possible to prove a causal
relationship between the
detection of KIV and WUV
and respiratory disease from
these findings
X(a) X(a) 1,326 hospitalized
children with acute
respiratory diseases
4.9% positive WUPyV. 56%
were co-infections with
other viruses (ADV, fluA,
hBoV and RSV).
X(b) X(b) 153 HIV-1-infected
patients (mean age
42 years), 130 controls
2.6% KIPyV positive and 4.6%
WUPyV positive among
HIV-1–infected patients
compared with 3.1% KIPyV
positive and 0,8% WUPyV
positive in blood donors.
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No association found between
CD4+ cell counts in HIV-1
positive patients and infection
with KIPyV or WUPyV






0.79% KIPyV, 0.79% WuPyV
positive among transplant
recipients; 1.4% KIPyV and 0.2%
WUPyV in children. WU/KIPyVs
have a low pathogenic
potential in young children.
Brief and asymptomatic
infection can occur in
hematopoietic transplant
recipients.
X(b) X(b) X(a) 771 children with acute
respiratory tract infection
and 82 samples from
healthy subjects
In most of infected children
single WUPyV infection was
detected.It suggests that the
newly described polyomavirus
can cause acute respiratory
tract infection





Prevalence of WUPyV and
KIPyV is similar in hematology/
oncology patients (3% and
5.6%, respectively) compared
with the general pediatric
population (5%and 2.3,
respectively). High co-detection
rates with other viruses
(RSV and HRV) in both groups.
Higher viral loads for KIPyV
(but not for WUPyV) in the
immunocompromised group
was detected and infection
with either virus occurred in
older children compared with
controls, which may suggest
viral-reactivation





HRV-C is an important cause of
febrile wheeze and asthmatic
exacerbations in children
requiring hospitalization.
No clear clinical difference
has been noted between
single or mixed HRV-C
infections




High rate of coinfections,
ow frequency of detection
and lack of clear disease
associations indicate that




X(a) X(a) X(a) X(a) X(a) X(a) 406 children< 14 years
with RTI
13% HRV positive (22% HRV-A,
12% HRV-B, 19% HRV-C).
Monoinfection was observed
in more than half of cases,
HRV-C is an important cause
of RTIs in children. Patients
infected with HRV-C may
exhibit different clinical






HRVCs were detected in 7% of
children hospitalized for fever
or respiratory conditions and
constituted almost half of all
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Table 1 Recent epidemiological papers on respiratory infections and co-infections (Continued)
HRVs-associated
hospitalizations, suggesting
that this novel group causes
a substantial burden of
pediatric disease
3,800 children aged
2 to 13 years with
respiratory illness
EV109 isolates were then
detected in 1.6% of
respiratory samples of
children with influenza
like illness (ILI) and
recognized to have a
pathogenetic role in
the illness
X(a) X(a) X(a) X(a) X(a) X(a) X(a) X(a) 1149 nasopharingeal
aspirates
HEV109 infection may be
associated to ARDs both




X(a) X(a) X(a) X(a) X(a) X(a) X(a) X(a) 3,525 patients with
respiratory syndrome
The prevalence of HpeV
is 0.4%. The most
commonly identified
HPeVs were HpeV1(58%)
and HpeV3 (37%). Although
not circulating at high
frequency and unlikely to
cause respiratory syndrome,
HPeV was associated with
severe clinical syndromes in
a minority of newborns.
The frequent association
of HPeV with other respiratory
viruses may indicate a less
pathogenic role for HPeV
compared to the other viruses
X(a) X(a) X(a) 56 adults and 39 children
visited for influenza-like
illnesses
31% of H1N1 infections, 16%
coinfected with HRV (60%)
and RSV, CoV229E, HBoV (20%).
No difference in disease




The presence of HRV reduce
the risk of H1N1 infection.
X(a) X(a) X(a) X(a) in adult and paediatric
patients with Influenza-like
illness (413)
16% of H1N1 infections, 19% of
them were co-infections
(mainly HRV). Among 50% of
non-H1N1 infections were
HRV infections and increase
of H1N1 cases was associated
with rapid HRV infection decline
(a) qualitative molecular detection; (b) quantitative molecular detection; (c) cell culture; (d) Immune Fluorescence; (e) serology.
The pathogens analyzed and the methods used for detection as well as the population characteristics and the main conclusions are reported. The principal
pathogen under evaluation is indicated in bold. Flu=influenza virus; HRV= human rhinovirus; HEV= human enterovirus; HpeV= human parechovirus;
PIV= parainfluenza virus; hMPV=human metapneumovirus; ADV=adenovirus; RSV=respiratory syncytial virus.
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gency department in Germany [89]. Don et colleagues
[76] found serological evidence of an acute HBoV infec-
tion in 12% of children with pneumonia and in more
than half of these cases with single HBoV infection. In
most cases a significant rise in IgG antibodies between
paired sera was found in children admitted to hospital
for radiologically confirmed pneumonia. IgM antibodies
were also detected in all but one patient. This studysuggests that HBoV may be a fairly common cause of
pneumonia in children Table 1.
KI and WU Polyomaviruses
Two new polyomaviruses were identified in 2007 in re-
spiratory tract samples following large scale molecular
screening using high throughput DNA sequencing of
random clones [5,7] and have been named after the in-
stitutes where they were found: KI (Karolinska Institute)
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polyomavirus (WUPyV). Data on seroprevalence indicate
that infection is widespread ranging from 54.1 and 67% for
KI and from 66.4% and 89% for WU in North American
and German blood donors [90,91]. Since their first iden-
tification, KI and WU viral sequences have been con-
firmed worldwide in respiratory samples from children
with respiratory tract disease ranging from 0.2% to 2.7%
and from 1.1 to 7%, respectively [91-97]. However
WUPyV and KIPyV were found at similar frequencies in
control groups without respiratory diseases so the link
between these polyomaviruses and acute respiratory dis-
eases remains speculative [94,96,98].
Careful analysis is complicated by high co-infection
rates with other well-characterized viral respiratory
pathogens. A co-detection rate of 74% has been
observed for KIPyV and rates ranging from 68 to 79%
for WUPyV [94,95,97]. Therefore, in a recent study in
Southern China, hospitalized children with WUPyV in-
fection displayed predominantly cough, moderate fever,
and wheezing, but were also diagnosed with pneumonia,
bronchiolitis, upper respiratory tract infections and
bronchitis. As in most of infected children a single
WUPyV infection was detected, it was suggested that
the newly described polyomavirus can cause acute re-
spiratory tract infection with atypical symptoms, includ-
ing severe complications [99]. Nevertheless these data
have to be confirmed in further studies.
The presence of WUPyV and KIPyV in samples from
children but not from immunocompetent adults suffer-
ing from LRTIs suggests that these viruses primarily in-
fect the young population [100]. A correlation between
immunosuppression and reactivation of the two novel
polyomaviruses has been suggested in immunocom-
promised patients [101] and in AIDS patients at the mo-
lecular level [102], but no evidence of a role of these
viruses as opportunistic pathogens has been given.
Overall, these data support the hypothesis that, in ana-
logy with BK and JC polyomaviruses, KIPyV and
WUPyV can establish persistent infection, and that virus
replication may increase in immunocompromised hosts.
However, in a recent study on immunocompetent and
immunocompromised adult patients, real-time PCR
detected KIPyV and WUPyV in 2.6% and 4.6% of HIV-
1–infected patients respectively and in 3.1% and 0.8% of
blood donors respectively, while no association was
found between CD4+ cell counts in HIV-1 positive
patients and infection with KIPyV or WUPyV [103].
KIPyV and WUPyV are also incidentally detected in
adults with community acquired pneumonia, in im-
munocompromised hosts, and in patients with lung can-
cer; they are more often found in patients suffering an
underlying medical condition and coinfections with
KIPyV and WUPyV with other respiratory viruses arecommon [92,103,104]. A recent study evaluating the
prevalence and viral load of WUPyV and KIPyV in re-
spiratory samples from immunocompromised and im-
munocompetent children showed that the prevalence of
WUPyV and KIPyV is similar in hematology/oncology
patients compared with that of the general pediatric
population [105]. High co-detection rates with other re-
spiratory viruses, mainly RSV and enterovirus or rhino-
virus, were found for WUPyV and KIPyV in both
groups, in analogy with previous reports. However,
higher viral loads for KIPyV in the immunocomprom-
ised group were detected, suggesting that there may be
an increased replication of this virus in this population.
A similar association was not observed for WUPyV. Fur-
thermore, in the immunocompromised group, infection
with either virus occurred in older children compared with
controls, which may indicate viral-reactivation Table 1.
Rhinovirus, Enterovirus and Parechovirus
Rhinoviruses
HRVs are currently classified in the Picornaviridae fam-
ily, genus Enterovirus, that includes 3 species: HRV-A,
HRV-B, and HRV-C. Within each species there are mul-
tiple HRVs designated as “serotypes”, “types”, or
“strains”. Several recent epidemiological studies suggest
that HRV-A and HRV-C are the predominant species
associated with acute respiratory illnesses in hospitalized
children and adults, compared to HRV-B which are
rarely detected [106].
The new HRV lineage designated HRV-C has been iden-
tified using molecular methods and associated with severe
clinical presentations in infants and immunocompromised
adults. Symptoms of patients infected with this new strain
were mainly bronchiolitis, wheezing, and asthmatic ex-
acerbation in cases from Australia and Hong Kong, which
peaked in fall and winter whereas in New York the new
rhinovirus genotype was detected in cases of influenza like
illness (ILI) that were clustered within an 8-week period
from October to December [62,107,108]. A recent study
describes a clinical case of severe respiratory and pericar-
dial disease in an infant infected by HRV-C suggesting tha
viral tropism is not strictly restricted to the respiratory
tract [109]. A study focusing on the global distribution of
novel rhinovirus indicates its association with community
outbreaks and pediatric respiratory disease also in Africa
and in symptomatic subjects living in remote locations
having limited contacts with other human populations.
Moreover evidence for a role of HRV-C in lower respira-
tory tract disease and febrile wheeze in infants and asthma
exacerbations in older children was reported [110-114].
Recent studies making comparisons between HRVs spe-
cies, found the HRV Cs more so than As or Bs as the
major contributors to febrile wheeze and asthma exacer-
bation in infants and children, respectively . However, the
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able to that for HRV-A in children with community-
acquired pneumonia [115]. In HRV C studies so far, no
clear clinical difference has been noted between patients
with single or mixed HRV-C infection [111,113,116]. In a
study, monoinfection was observed in more than half of
cases and was more common than RSV monoinfection in
patients with upper RTD, however the duration of hospi-
talizations was not significantly different between the
HRV-C monoinfection group, HRV-A or HRV-B monoin-
fection group and RSV group suggesting that HRV-C is an
important etiological factor in children with RTI [117].
Most HRV-C co-detections are with RSV [113,117-119],
however in a large study HRVs were statistically the least
likely virus of 17 examined to be associated with co-
infections [120] Table 1.
Enteroviruses
A novel HEV (EV104) genotype was first identified in
Switzerland in 2010 from respiratory samples collected
during 2004–2007 in 8 children with respiratory signs
and symptoms and acute otitis media [121]. In a follow-
ing epidemiologic study conducted in Italy, five strains
of the new EV104 genotype were detected in patients
with respiratory diseases [122]. Patients were aged 2 to
62 years and most had underlying diseases; in immuno-
competent patients EV104 was associated with chronic
rhinopharyngytis, whereas in immunocompromised pa-
tients with symptoms of acute respiratory tract infection
including wheezing, fever and rhinorrhea. Only in one
out of 5 patients a coinfecting virus was detected.
EV109 was first discovered from a case of acute re-
spiratory illness in a Nicaraguan child in September
2010; EV109 isolates were then detected in 1.6% of re-
spiratory samples of children with influenza like illness
(ILI) in Managua, and recognized to have a pathogenetic
role in the illness [2]. After this characterization, a spe-
cies C of HEV distantly related to EV109 was retrieved
from a rectal swab of a deceased patient during an out-
break of flaccid paralysis in Congo; in this sample polio-
virus and other neurologic, enteric and respiratory viral
pathogens were not detected [123]. The global distribu-
tion of EV 109 is currently unknown and only a few
studies have been performed yet to evaluate epidemio-
logical features of this infection. [124,125] To date the
pathogenic role of these new enterovirus strains has still
to be defined in larger clinical and epidemiological sur-
veys Table 1.
Parechoviruses
There are fourteen known HPeV genotypes that were
isolated mainly in young children [126-134]
Two recent studies have investigated the involvement of
HPeVs in respiratory diseases reporting a low frequency ofdetection and a lack of clear disease association [135,136].
Both studies detected HPeV infections mostly in chil-
dren below 5 years and the most commonly identified
parechoviruses were HPeV1 and HPeV3, while HPeV4,
HPeV 5 and HPeV 6 were detected in a minority of
cases. However, in addition to a low HPeVs prevalence
in respiratory samples, a high rate of co-infection with
other respiratory viruses was observed in HPeV posi-
tive samples, making it difficult to define a pathogenic
role of these new HPeV genotypes in child respiratory
infections.
Pandemic A/H1N1v influenza 2009
In March 2009, a novel reassortant influenza strain (A/
H1N1v) was discovered in Mexico as an infective agent
in humans [137,138]. From April 15 through May 5,
2009, a total of 642 confirmed cases of human infection
with the outbreak strain of H1N1v were identified in 41
states in the USA [139,140]. Of the patients with con-
firmed infection, 9% required hospitalization. The age of
hospitalized patients ranged from 19 months to 51 years
and among the hospitalized patients for whom data were
available, 18% were children under the age of 5 years.
Multiple reports have described the clinical features of
infection with this novel virus, which are similar or
milder to those of seasonal influenza, [141,142]. The
spectrum of clinical presentation varies from self limit-
ing respiratory tract illness in most cases, to primary
viral pneumonia resulting in respiratory failure, acute re-
spiratory distress, multi-organ failure and death, most of
them occurring in patients with underlying medical con-
ditions [142].
During the A/H1N1v flu wave, due mainly to the lack
of cross-neutralizing anti-influenza antibodies [143,144]
or the presence of co-morbidities, more children and
younger adults were infected by the pandemic flu strain
and had serious disease than in the seasonal epidemic.
For this reason they were identified as a particular risk
group, together with pregnant women [145,146]. Young
children presented a higher attack rate than older adults
and a greater mortality rate than previously observed
with classical seasonal flu [147,148]. In a study conducted
in England from June 2009 to March 2010, a childhood
mortality rate of 6 per million population was reported.
The rate was highest for children less than 1 year and
with severe pre-existing disorders [149]. Similar data are
reported in other studies highlighting that most severe
cases occurred in children with known comorbidities
[150-153].
The occurrence of co-infection with influenza A
H1N1v and other respiratory viruses has been reported
in few studies. In a study conducted in France and aimed
at investigating respiratory pathogens involved in ILI dur-
ing the early weeks of the 2009–29010 H1N1v diffusion,
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other respiratory pathogens. In mixed infections, HRV
was the more frequent co-pathogen being detected in
13.2% of all samples positive for H1N1v [154]. However,
HRV infections represented nearly half of non-H1N1v
viral infections and the increase of H1N1v positive cases
was associated with a rapid decline of HRV infections.
In addition, the frequency of virus co-infection was
slightly but not significantly higher in samples positive
for H1N1v as compared with samples positive for other
respiratory pathogens and viral mixed infection both
with H1N1v and other viruses was not associated with
a different clinical presentation. Similar co-infection
data are reported in a prospective study evaluating a
combination of two RT-PCR DNA microarray systems
in virological routine diagnosis of ILI [155]. In both
studies conducted in France, in the same H1N1v early
pandemic period, few RSV infections were reported
compared with epidemiological data in the same period
of the last four years. The delayed and reduced circu-
lation of RSV observed in 2009–10 compared with
2008–09 suggests that the early circulation of the 2009
pandemic influenza A(H1N1) viruses had an impact on
the RSV epidemic [156]. A significant inverse relation-
ship between HRV and A H1N1 pandemic virus was also
reported, suggesting that the presence of HRV reduces
the risk of infection by the H1N1 virus and thus, in-
directly, the spread of the virus [156] Table 1.Orphan viruses
Torque tenovirus (TTV), is classified in the new genus
Anellovirus [157]. TTV produces long-lasting (possibly
life-long) viremia in about 80% of apparently healthy
individuals of all ages and living in different countries
[158]. Although no evidence was obtained that TTV is a
direct cause of acute respiratory diseases, it was ob-
served that average viral loads are considerably higher in
children with bronchopneumonia than in children with
milder illnesses, regardless of the presence of common
respiratory viruses [159]. Further studies could not con-
firm the association, but documented a link between
TTV infection in children and asthma, suggesting that
TTV might be a contributing factor in the lung impair-
ment caused by this condition [160]. Finally, it was
documented that TTV is able to infect respiratory cili-
ated cells and that these cells are potentially able to sup-
port viral replication [161]. Far from being conclusive,
the data suggest that these viruses may replicate ef-
ficiently in the respiratory tract of children with and
without acute respiratory infections by other respiratory
viruses, and that although TTV does not have a clear
pathogenic role in acute respiratory diseases, it may in-
fluence the clinical presentation of the disease.Conclusions
Over the past 10 years, advances in scientific knowledge
and the availability of new technologies have deeply
changed our views in the field of respiratory viral infec-
tions. In particular, the identification of new viruses or
viral strains has allowed to better define the viral etio-
logy in many respiratory diseases where the viral patho-
gen was only hypothesized or suspected.
Molecular virological diagnosis has thus gained an
increasing importance with the development of novel
molecular assays, in some cases able to detect many
respiratory viruses simultaneously.
Nevertheless, despite the availability of novel diagnos-
tic assays, data are still controversial regarding the role
of coinfection in a more severe clinical outcome in com-
parison to single infections.
In this context, even though specific antiviral com-
pounds or vaccines are being developed, the level of ac-
curacy and the associated higher costs of complex
molecular assays to highlight the presence of one or
more viruses in the same samples, are often considered
not to be clinically necessary.
However, some important considerations emphasize
the importance of implementing diagnostic approaches
that allow the identification of the greatest number of
newly identified or emerging viral respiratory patho-
gens. Firstly, the use of diagnostic assays able to simul-
taneously detect more respiratory viruses, including the
newly identified ones, and in some cases their load, will
help to clarify virus-host interactions which are still
partially unknown, in particular in hospitalized patients.
This will allow to develop appropriate control measures
for nosocomial infection containment. Moreover, in many
cases respiratory viruses pave the way to severe second-
ary bacterial infections. Thus the rapid identification of
viral pathogens may help to limit disease progression
and to plan appropriate monitoring and patient man-
agement in defined clinical settings. Furthermore, rapid
and reliable screening with large panel of respiratory
viruses responsible for upper and lower RTIs is of ma-
jor epidemiological and clinical interest for monitoring
influenza pandemic waves or unexpected respiratory
outbreaks.
In addition, in the case of emerging viral strains as
well as for enteroviruses, parechovirus or rhinoviruses
the subsequent or simultaneous circulation of genetic-
ally distinct strains with distinct pathogenic potential,
suggests a high risk for repeated pediatric respiratory
infections as well as the possibility of genetic recom-
bination within species. In these cases, the continuous
development of quantitative assays associated with viral
genotyping assays will allow the rapid and valuable eti-
ological diagnosis of enterovirus, parechovirus or rhi-
novirus childhood infections, helping to prevent both
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of new respiratory strains with unpredictable pathogenic
potential.
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